Sonoma Pharmaceuticals (SNOA) Expected to Announce Quarterly Earnings on Thursday

Sonoma Pharmaceuticals (NASDAQ:SNOA) is expected to issue its results before the market opens on Thursday, August 6th. Analysts expect Sonoma Pharmaceuticals to announce earnings of ($0.30) per share and revenue of $4.99 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Tuesday, June 16th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). The firm had revenue of $5.56 million for the quarter, compared to analysts’ expectations of $5.57 million. Sonoma Pharmaceuticals had a negative net margin of 16.26% and a negative return on equity of 43.95%.

Sonoma Pharmaceuticals Stock Performance

SNOA stock opened at $1.12 on Tuesday. The stock has a fifty day moving average of $1.16 and a 200-day moving average of $1.93. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92. The company has a market capitalization of $5.36 million, a price-to-earnings ratio of -0.59 and a beta of 1.28.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC grew its stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,977 shares of the company’s stock after buying an additional 43,907 shares during the period. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.